Barclays Issues Pessimistic Forecast for Avantor (NYSE:AVTR) Stock Price

Avantor (NYSE:AVTR) had its price objective decreased by Barclays from $26.00 to $23.00 in a research report released on Monday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

Other equities analysts have also issued research reports about the company. UBS Group restated a “neutral” rating and set a $25.00 price target (down previously from $29.00) on shares of Avantor in a research note on Friday, January 17th. Wells Fargo & Company reduced their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Raymond James dropped their price objective on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Finally, Robert W. Baird reduced their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.15.

Avantor Stock Performance

NYSE:AVTR opened at $19.00 on Monday. The firm has a market capitalization of $12.93 billion, a PE ratio of 41.30, a PEG ratio of 3.87 and a beta of 1.28. The stock’s fifty day moving average is $21.73 and its 200 day moving average is $23.47. Avantor has a fifty-two week low of $18.49 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54.

Avantor (NYSE:AVTR) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same quarter in the previous year, the company posted $0.22 earnings per share. On average, sell-side analysts anticipate that Avantor will post 0.98 earnings per share for the current year.

Institutional Trading of Avantor

Several institutional investors have recently modified their holdings of the stock. State Street Corp increased its position in shares of Avantor by 58.0% during the third quarter. State Street Corp now owns 22,368,244 shares of the company’s stock worth $578,666,000 after purchasing an additional 8,206,695 shares in the last quarter. Janus Henderson Group PLC increased its stake in Avantor by 18.2% during the third quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock worth $457,710,000 after acquiring an additional 2,719,615 shares during the last quarter. Geode Capital Management LLC lifted its position in Avantor by 7.1% in the third quarter. Geode Capital Management LLC now owns 11,150,788 shares of the company’s stock valued at $287,791,000 after buying an additional 739,667 shares during the last quarter. Robeco Schweiz AG boosted its position in shares of Avantor by 12.5% during the 4th quarter. Robeco Schweiz AG now owns 7,612,555 shares of the company’s stock worth $160,397,000 after purchasing an additional 848,814 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Avantor by 653.0% in the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock valued at $159,740,000 after buying an additional 5,354,678 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.